COMMUNIQUÉS West-GlobeNewswire

Tabula Rasa HealthCare Acquires Mediture and eClusive
04/09/2018
Mediture’s Electronic Health Record software solution and eClusive’s third party administrator services will expand TRHC’s presence in the PACE market and with other At-risk Providers MOORESTOWN, N.J., Sept. 04, 2018 ( [...]
BrainStorm Appoints Arturo Araya as Chief Commercial Officer
04/09/2018
Mr. Araya was Global Head of Commercial of Novartis Cell & Gene Therapies Unit Appointment strengthens leadership team with nearly 20 years of global pharmaceutical marketing and commercialization experience NEW [...]
Alavida continues rapid expansion across Canada: Now in Manitoba
04/09/2018
WINNIPEG, Manitoba, Sept. 04, 2018 (GLOBE NEWSWIRE) -- On the heels of their most recent financial raise, Alavida Health - a science-based innovative outpatient treatment for Heavy Drinking, expands its operations to [...]
Vistin Pharma ASA : Q2 2018 presentation
04/09/2018
Oslo, Norway, 4 September 2018 Reference is made to the release of the second quarter 2018 results on 30 August 2018 for Vistin Pharma ASA. Please find attached the investor presentation held today at Carnegie in [...]
Sanofi: Disclosure of trading in own shares
04/09/2018
Attachment Reporting EN.pdf
Sanofi : Déclaration des transactions sur actions propres
04/09/2018
Pièce jointe Reporting FR.pdf
Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction
04/09/2018
CHARM study will evaluate IV glibenclamide for the prevention and treatment of severe cerebral edema in LHI, one of the most severe types of ischemic stroke with limited treatment options Prior studies demonstrated IV [...]
Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors
04/09/2018
BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that its Board of Directors has nominated Scott Braunstein, M.D., an Operating Partner at Aisling Capital, a leading [...]
Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy
04/09/2018
PHAROAH Trial Results to-Date Show APL-2 Monotherapy Eliminated Transfusion Dependency and Improved Markers of Anemia in PNH Patients on Soliris™ CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- [...]
Mustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018
04/09/2018
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric [...]
AxoGen, Inc. Appoints Angelo G. Scopelianos, Ph.D. as Vice President, Research and Development
04/09/2018
ALACHUA, Fla., Sept. 04, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced [...]
BeyondSpring to Present at the H.C. Wainwright 20th Annual Global Investment Conference
04/09/2018
NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that [...]
RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA® for H. pylori Infection
04/09/2018
Top-line results from the randomized, double-blind confirmatory Phase III study (ERADICATE Hp2 study) with TALICIA ® are expected before year’s end The ERADICATE Hp2 study enrolled 455 patients with confirmed H. pylori [...]
Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
04/09/2018
Exceeded Enrollment Target with 15 Patients in Phase 1/2 Trial Additional Interim Data to be Presented at ASHG Conference in October 2018 Company Plans to Announce Pivotal Trial Design in Q4 2018 and Initiate Pivotal [...]
BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks
04/09/2018
—Safety and efficacy data support advancement of 750 mg dose as first oral therapy for acute HAE attacks— RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) [...]
Soricimed Announces Changes to its Board of Directors
04/09/2018
MONCTON, New Brunswick, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing targeted cancer therapeutics, is pleased to announce [...]
Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
04/09/2018
Two Sites in the UK Currently Enrolling Patients FREMONT, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cellular [...]
Helius Medical Technologies Submits Request for FDA 510(k) Clearance of the PoNS™ Device
04/09/2018
NEWTOWN, Pa., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the [...]
Aleafia Secures Sales Licence from Health Canada
04/09/2018
TORONTO, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: ALEF; OTCQX: ALEAF) (“Aleafia“) or (the “Company“), one of Canada’s leading, vertically integrated medical cannabis companies with a unique patient- [...]

Pages